Most people with tuberculosis (TB) live in settings with limited diagnostic capacity, which contributes to delays in diagnosis and treatment and ongoing community transmission. Existing diagnostics commonly rely on sputum samples, but some people with presumptive TB cannot produce an adequate sputum specimen. New near-point-of-care (NPOC) molecular tests that can use sputum or alternative sample types such as tongue swabs may increase access to timely diagnosis. The EVIDENT trial protocol describes a pragmatic evaluation of introducing one such test—the NPOC MiniDock MTB test—within a multi-component public health intervention in Indonesia.
EVIDENT is a pragmatic cluster randomised controlled trial conducted in Bandung District, Indonesia. Forty community health centre (CHC) areas will be randomised in a 1:1 ratio to either the intervention or control arm. The intervention will be implemented both in healthcare facilities (HCFs) within intervention areas and in community settings in those areas. Control areas will continue with local standard of care, with a single exception: both intervention and control areas will receive TB notification refresher training before the intervention roll-out.
The trial will compare TB diagnostic and notification activity measured in routine data for the 12 months after completion of intervention roll-out with the 12 months preceding any trial activities.
The intervention is multi-component and designed to address diagnostic access, clinical decision-making, patient engagement, and active case finding. The four components are:
Introduction of the NPOC MiniDock MTB test (Guangzhou Pluslife Biotech, China) for use on sputum, tongue swab, or both specimen types in HCFs and community settings.
Optimisation of clinical algorithms to incorporate the new test into diagnostic workflows. The protocol describes adapting algorithms so clinicians and community workers can use the NPOC test results in patient management.
A promotional package intended to encourage patient attendance at services and utilisation of the new test. The promotional activities will support uptake of the test but specific promotional materials or strategies are not detailed in the abstract.
TB household contact investigation conducted by community health volunteers, which will include use of the NPOC test as part of contact assessment in intervention areas.
These components are implemented as a package to evaluate the combined effect on case detection and notification rather than the independent contribution of each element.
Forty CHC areas will be stratified and randomly allocated to intervention or control arms on a 1:1 basis. The intervention arm receives the multi-component package described above. The control arm continues standard of care; however, both arms receive TB notification refresher training prior to roll-out to reduce baseline differences in notification practices attributable to training.
Randomisation at the CHC area level preserves pragmatic delivery through existing health system structures and allows measurement of outcomes at facility and population levels.
The primary outcome is the number of TB cases diagnosed and notified by healthcare facilities, expressed relative to the population attending those facilities. This will be measured by abstracting routine TB case notification data and the number of facility attendees for the 12 months following completion of intervention roll-out, and comparing those data with the 12 months prior to any trial activities.
The trial seeks to determine whether the introduction of the NPOC test and supporting programme increases diagnosis and notification compared with standard care, thereby informing policy decisions about adoption of NPOC testing and associated programmatic changes.
The protocol reports initial ethical approval from the Research Ethics Committee, Universitas Padjadjaran Bandung (Number 467/UN6.KEP/EC/2025) on May 21, 2025. A protocol amendment was subsequently reviewed and approved by the same committee (Number 7/UN6.KEP/EC/2026) on February 5, 2026. The trial is registered on ClinicalTrials.gov under identifier NCT07293455. The authors declare no competing interests.
The manuscript confirms that participant consent and appropriate approvals were obtained and that reporting guidelines were followed where applicable.
The protocol notes that no datasets were generated or analysed during the current study stage described in the preprint. All relevant data from the trial will be made available upon study completion. Because this document is a preprint and has not been peer reviewed, its findings and procedural details should not be used to guide clinical practice until trial results are published and evaluated.